Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Quantification des plaques dérivées de l'IA : CCTA et AI-QCPA pour déterminer une gestion efficace de la CAO (DECIDE)

17 novembre 2026 mis à jour par: HeartFlow, Inc.

Registre DECIDE : Quantification des plaques dérivées de l'IA : CCTA et AI-QCPA pour déterminer une gestion efficace de la CAO

The objective of HeartFlow's DECIDE Registry is to collect observational data about the management of patients before and after HeartFlow Artificial Intelligence-Quantitative Coronary Plaque Analysis (AI-QCPA).

Aperçu de l'étude

Description détaillée

The DECIDE Registry is a post-market, multi-center, data collection study assessing the change in management of clinically stable patients who undergo CCTA with plaque detected. Data will be retrospectively collected following the CCTA, and analyses will be completed 90 days, 180 days, and 1 year after CCTA. Data may be retrospectively collected annually up to 5 years.

Type d'étude

Observationnel

Inscription (Estimé)

20000

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • North Carolina
      • Greensboro, North Carolina, États-Unis, 27401
        • Moses Cone Memorial Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

Deidentified data will be collected for all patients who have had a CCTA with plaque detected or a stress test and are included by the site in the registry.

La description

Inclusion Criteria (all must be present) :

  1. Groups 1, 2,4,5 and 6: CCTA and plaque detected
  2. Group 3: Any patient with a stress test (stress echocardiogram or nuclear imaging including SPECT or PET) and no CCTA within the 90 days prior to site activation
  3. Groups 1,2,3 and 4: Clinically stable, symptomatic
  4. Group 6: Clinically stable without symptoms suggestive of CAD at the time of the CCTA

Exclusion Criteria (all must be absent) :

  1. ED presentation (at the time of the CCTA or stress test)
  2. Groups 1,2,3,4, and 6: Previous history of CAD (prior to the CCTA or stress test with history of revascularization)
  3. Group 5: Prior history of PCI in multiple vessel territories, PCI in the Left Main, CABG, and/or any other conditions or limitations which would prevent successful CCTA processing by HeartFlow
  4. Acute chest pain (in patients who have not been ruled out for ACS)
  5. Previously evaluated with and/or in a study which includes AI-QCPA

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: CROSS_SECTIONAL

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Group 1: No AI-QCPA

This group includes previously scanned, symptomatic patients with plaque detected and no prior revascularization. No AI-QCPA will be provided.

Group 2: Delayed AI-QCPA

This group includes previously scanned, symptomatic patients with plaque detected and no prior revascularization. Ninety days following the CCTA, an AI-QCPA report will be provided to the CCTA reader who will in turn provide it to the treating clinician. The treating clinician will decide if changes to medical management are required to effectively treat the patient and if so, treating clinician will contact the patient with the new treatment plan.

The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.

Group 3: Stress Test Only

This group includes symptomatic patients who previously had non-invasive stress testing only with no CCTA and no prior revascularization. No AI-QCPA will be provided.

Group 4: Prospective AI-QCPA, symptomatic without prior revascularization

This group includes newly scanned, symptomatic patients with plaque detected and no prior revascularization. Patients in this group will have current symptoms suggestive of CAD and will not have had prior revascularization. CCTA reader who identifies plaque orders AI-QCPA to inform the medical management plan for the patient.

The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.

Group 5: Prospective AI-QCPA, prior PCI

This group includes newly scanned patients with plaque detected. Patients in this group can by symptomatic or asymptomatic and will have had prior PCI in only one vessel territory (CABG patients are not eligible). CCTA reader who identifies plaque orders AI-QCPA to inform the medical management plan for the patient.

The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.

Group 6: Prospective AI-QCPA, asymptomatic without prior revascularization

This group includes newly scanned, asymptomatic patients with plaque detected and no prior revascularization. Patients in this group will not have current symptoms suggestive of CAD and will not have had prior revascularization. CCTA reader who identifies plaque orders AI-QCPA to inform the medical management plan for the patient.

The HeartFlow Plaque Analysis provides plaque identification, quantification, and characterization and is meant to support qualified clinicians to aid in the evaluation and risk assessment of coronary artery disease (CAD). It provides data on the volume and type of plaque present (Calcified, Non-calcified, Low Attenuation), both vessel specific and total volumes, with which physicians can better understand a patient's risk, discuss heart health, and help optimize medical management. Plaque Analysis is calculated using image data from a previously acquired CCTA.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Primary Endpoint
Délai: 90 Days

The primary endpoint of the DECIDE Registry is the change in medical management following HeartFlow AI-QCPA at 90 days compared to medical management following CCTA alone. The primary endpoint will only be assessed in patients in Group 2.

90 Days

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in LDL levels
Délai: From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups

From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Change in HbA1c levels
Délai: From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups

From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Changes in Non HDL levels
Délai: From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups

From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Changes in HDL levels
Délai: From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups

From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Changes in TG levels
Délai: From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups

From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Changes in weight
Délai: From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups

From baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Reclassification rate of medical management (across the groups)
Délai: 90 Days, 180 Days and 365 Days

Change in preventive medical management (lower or intensify).

90 Days, 180 Days and 365 Days
Rates of referral to invasive coronary angiography and coronary revascularization (PCI+CABG)
Délai: 90 Days, 180 Days and 365 Days

across the groups

90 Days, 180 Days and 365 Days
Reclassification rate of symptoms
Délai: 90 Days, 180 Days and 365 Days

Improvement in symptoms across the groups

90 Days, 180 Days and 365 Days
Number of CV hospitalizations
Délai: At 365 Days (and potentially out to 5 years)

across the groups

At 365 Days (and potentially out to 5 years)
Number of Revascularizations
Délai: 365 Days

At one year across the groups

365 Days

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Number of MACE (CV-related death, MI, or CAD hospitalization)
Délai: At 365 Days (and potentially out to 5 years)

Exploratory & safety endpoints will be compared across the groups unless otherwise noted

At 365 Days (and potentially out to 5 years)
Timing of referral to other provider(s) for management
Délai: Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA

across the groups unless otherwise noted

Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA
Timing of lab orders (Group 1 vs. Group 2)
Délai: Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA

across the groups unless otherwise noted

Group 1 vs. Group 2 at 90 days post AI-QCPA and Group 2 vs. 4 at 90 days post AI-QCPA
Change in Lp(a) (Group 2)
Délai: Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups unless otherwise noted

Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Change in Lp(a) (Group 4 compared to Group 1)
Délai: Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days

across the groups unless otherwise noted

Baseline to 90 days, from 90 days to 180 days, and 90 days to 365 days
Rate of cardiac testing
Délai: At 365 Days (and potentially out to 5 years)

Efficiency of testing based upon imaging and reports for all other cardiac tests including CCTA, SPECT, echo, CAC, and stress echo

At 365 Days (and potentially out to 5 years)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Sarah Rinehart, MD, CAMC Health System
  • Chercheur principal: Leslee Shaw, MD, MOUNT SINAI HOSPITAL

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

27 mars 2024

Achèvement primaire (Réel)

27 mars 2026

Achèvement de l'étude (Estimé)

27 mars 2030

Dates d'inscription aux études

Première soumission

28 mars 2024

Première soumission répondant aux critères de contrôle qualité

17 avril 2024

Première publication (Réel)

19 avril 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

17 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner